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Objectives: Our 2007 study of 32 patients with ovarian cancer reported the possible in-
volvement of tissue factor (TF) in the development of venous thromboembolism (VTE)
before treatment, especially in clear cell carcinoma (CCC). This follow-up study further
investigated this possibility in a larger cohort.
Methods: We investigated the intensity of TF expression (ITFE) and other variables for
associations with VTE using univariate and multivariate analyses in 128 patients with epi-
thelial ovarian cancer initially treated between November 2004 and December 2010, none of
whom had received neoadjuvant chemotherapy. Before starting treatment, all patients were
ultrasonographically screened for VTE. The ITFE was graded based on immunostaining of
surgical specimens.
Results: Histological types were serous carcinoma (n = 42), CCC (n = 12), endometrioid
carcinoma (n = 15), mucinous carcinoma (n = 53), and undifferentiated carcinoma (n = 6). The
prevalence of VTE was significantly higher in CCC (34%) than in non-CCC (17%, P = 0.03).
As ITFE increased, the frequencies of CCC andVTE increased significantly (P G 0.001 andP =
0.014, respectively). Multivariate analysis identified TF expression and pretreatment dimerized
plasmin fragment D level as significant independent risk factors for VTE development. These
factors showed particularly strong impacts on advanced-stage disease (P = 0.021).
Conclusions: The 2007 cohort was small, preventing multivariate analysis. This study of a
larger cohort yielded stronger evidence that the development of VTE in epithelial ovarian
cancer may involve TF expression in cancer tissues.
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Venous thromboembolism (VTE) is known to occur as aperioperative complication, particularly after intrapelvic
and intra-abdominal surgeries.1 Venous thromboembolism
also occurs readily after surgery for ovarian cancer.2 In 1865,
Trousseau3 reported that, for some patients with cancer in a
hypercoagulable state, the cancer can actually cause VTE. We
reported that VTE (mainly subclinical) develops before the
start of treatment in 26.7% of patients with ovarian cancer,
9.9% of patients with endometrial cancer, and 4.8% of pa-
tients with cervical cancer.4Y6 In terms of histological type, the
frequency of VTE occurring before the start of treatment of
ovarian cancers is significantly higher for clear cell carcinoma
(CCC) (50.0%) than for non-CCC (19.0%; P = 0.02), whereas
among endometrial cancers, the pretreatment frequency of
VTE is significantly higher in nonendometrioid adenocarci-
nomas including CCC (38.1%) than in endometrioid adeno-
carcinomas (6.0%; P = 0.0002).4,5
Tissue factor (TF), or blood coagulation factor III,
initiates extrinsic blood coagulation at the time of tissue
damage. Recent research has elucidated that TF is involved in
the hypercoagulable state seen in patients with malignant
tumors.7 In 2007, we performed immunohistochemical studies,
investigated the expression of TF in 32 patients with ovarian
cancer in our hospital, and reported the possibility that TF is
involved in the development of VTE in patients with ovarian
cancer before starting treatment.8 However, that study in-
cluded surgical specimens obtained from 15 patients after they
had undergone neoadjuvant chemotherapy (NAC), whereas
another patient had a yolk sac tumor in addition to epithelial
ovarian cancer (EOC). The validity of the results was thus
potentially limited by the inability to perform multivariate
analyses due to the small sample size. The cohort in this study
was increased in size and restricted to patients with EOC who
had not received NAC to clarify the relationship between TF
and the development of VTE using multivariate analysis.
MATERIALS AND METHODS
Study Population
The study protocol was approved by the ethics com-
mittee at the study hospital. All protocols were carried out in
accordance with the principles of the Declaration of Helsinki.
Participants were composed of 128 patients who underwent
initial therapy at the study hospital between November 2004
and December 2010 and had been pathologically given a
diagnosis of EOC. Informed consent was obtained from all
patients for the use of surgical specimens for research pur-
poses. The clinical stage of each specimen was decided in
accordance with the International Federation of Gynecology
and Obstetrics 2014 classifications. Although 181 patients
were treated during the study period, 53 patients who under-
went NAC were excluded considering the impact of anticancer
drug exposure on immunostaining in tumor cells. The clinical
stages of these 53 patientswere stage II in 2 patients, stage III in
33 patients, and stage IV in 18 patients. The histological types
were serous carcinoma in 45 patients, CCC in 5 patients,
mucinous carcinoma in 2 patients, and undifferentiated carci-
noma in 1 patient. Twelve patients in whom NAC was not
expected to lead to the total elimination of cancer in the initial
surgery, 23 patients in whom surgery needed to be cut short
because of complications including VTE or a poor general
condition, and 18 patients in the NAC group who took part in
a phase III trial of upfront debulking surgery versus NAC for
stage III/IV ovarian, tubal, and peritoneal cancers9 were ulti-
mately chosen for treatment, bringing the total number of
patients included in this study to 128.
Immunostaining was performed on surgical specimens
obtained from 126 patients who had undergone radical sur-
gery for EOC and biopsy tissues obtained from 2 patients who
had undergone exploratory laparotomy.
Immunohistochemistry
We performed immunostaining on tissue specimens
from all patients in this study, using the same technique
reported in our 2007 investigation.8 In brief, we prepared 3-mm-
thick sections from 3 sites of paraffin block specimens from
each patient. The anti-TF antibody (Cedarlane Laboratories,
Burlington, NC) used as the primary antibody was diluted
50-fold and biotinylated by the avidin-biotin-peroxidase
complex method (Vector ABC Elite kit; Vector Laborato-
ries, Burlingame, CA), followed by color development with
diaminobenzidine tetrahydrochloride. As positive controls, we
used sections of the umbilical cord, which is known to stain
brightly for TF,10 whereas negative controls were sections that
had been incubated in normal mouse serum.
The intensity of TF expression (ITFE) was graded into
the following 4 levels based on the proportion of all cell
populations that stained positively for TF: negative, no ap-
parent positive tumor cells; weakly positive, less than 50%
positive tumor cells; moderately positive, greater than or
equal to 50% positive tumor cells with weak intensity; and
strongly positive, greater than or equal to 50% positive tumor
cells with strong intensity (Fig. 1).11
All evaluations of the immunohistological results were
performed by 2 independent observers blinded to the results
of hematological examinations and histological diagnoses.
Mean values were used as the final values.
Detection of Deep Vein Thrombosis
Examination for VTE was performed using the same
method we have reported elsewhere.4,8 Leg vein ultrasonog-
raphy was performed on all patients using an ATL HDI5000
system (Philips Medical Systems, Bothell, WA) with a 3- to
7.5-MHz transducer, to detect deep vein thrombosis (DVT).
Output, pulse repetition frequency, and wall thump filter set-
tings were adjusted for venous vascular studies. Bilateral iliac,
femoral, great saphenous, popliteal, peroneal, posterior tibial,
and soleal veins were assessed for the presence/absence of
DVT. The iliac and femoral veins were examined with the
patient supine, whereas all other veins were assessed in the
upright position. All vessels were imaged in both short-axis
cross-section (transverse image) and long-axis cross-section
(longitudinal image). Manual compression using a transduc-
er and color Doppler imaging were performed to observe the
lumina of veins and search for blood clots. Pelvic veins were
also examined using the Valsalva maneuver. However, the
absence of a response to the Valsalva maneuver would raise the
suspicion of a blood flow disorder in the proximal vein, so
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thrombi in the pelvic veins were diagnosed based on the results
of contrast-enhanced computed tomography (CT). All patients
underwent extensive imaging using CT and magnetic reso-
nance imaging to detect the spread of pelvic tumors and blood
clots in the iliac veins and inferior vena cava.
Detection of Pulmonary Thromboembolism
All patients in whom DVT was detected on leg vein
ultrasonography or pelvic contrast-enhanced CTwere further
examined for the presence or absence of pulmonary throm-
boembolism on contrast-enhanced CT of the chest or pul-
monary blood flow scintigraphy using Tc-99.
Statistical Analysis
Categorical data are summarized as frequency and per-
centage, whereas continuous data are summarized as mean and
standard deviation. Categorical data were subjected to Fisher
exact test. Continuous data were tested using Student t test for
differences between 2 groups and by an analysis of variance for
comparisons of 3 or more groups. The development of VTE
was investigated using univariate and multivariate analyses
with a logistic model. Age, body mass index (BMI), stage,
pretreatment dimerized plasmin fragment D (D-dimer or DD)
level, histological type, and ITFE were used as variables in the
univariate analysis to identify potential risk factors for VTE
development. Variables showing significance were then
subjected to multivariate analysis. Variables showing strong
confounding suggestive of multicollinearity as well as a low
P value were selected and included in the multivariate anal-
ysis model. To evaluate the contribution of ITFE and his-
tology in each stage, we used additional multivariate models
that included ITFE, stage, and DD level; the interaction
between ITFE and stage; the interaction among histological
type, stage, and DD level; and the interaction between his-
tological type and stage. All analyses were performed using
SAS version 9.4 software (SAS Institute, Cary, NC), and
values of P G 0.05 were considered statistically significant.
RESULTS
Subject Characteristics
At the time of initial treatment, mean age was 56.6 years
(range, 31Y88 years), and mean BMI was 22.4 kg/m2 (range,
13.3Y35.4 kg/m2). Mean pretreatment DD level was 4.2 Kg/mL
(range, 0.1Y20.0 Kg/mL). For the 128 patients, stage was I in 55
patients, II in 22 patients, III in 37 patients, and IV in 14 patients,
whereas the histological type was serous in 42 patients, mu-
cinous in 12 patients, endometrioid in 15 patients, CCC in 53
patients, and undifferentiated in 6 patients (Table 1).
TF Expression in Cancer Tissues
Tissue factor was expressed in 71 patients (weakly
positive, n = 23; moderately positive, n = 32; strongly posi-
tive, n = 16), representing 55.5% of the 128 patients.
The ITFE did not correlate with patient age, BMI, or
pretreatmentDD level. According to stage, ITFEwas 81.8% for
stage I and 45.4% for stage II but was significantly lower for
stages III and IV, at 29.7% and 35.7%, respectively (P G 0.001).
Incidences according to histological type were 94.3% (50/53)
for CCC, 23.8% (10/42) for serous carcinoma, 26.7% (4/15) for
endometrioid carcinoma, 58.3% (7/12) for mucinous carcino-
ma, and 0%(0/6) for undifferentiated carcinoma.The ITFEwas
significantly higher in CCC than in non-CCC (P G 0.001) and
was also stronger in CCC (Table 2). As ITFE increased from
FIGURE 1. Immunohistochemical staining for TF in EOC tissues. A, Negative control. B, Weakly positive (G50%
positive tumor cells). C, Moderately positive (Q50% positive tumor cells with weak intensity). D, Strongly positive
(Q50% positive tumor cells with strong intensity). Percentages are based on the proportion of the entire tumor cell
population positive for TF. All pictures were taken at original magnification 200.
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negative to mild, moderate, and strong, the incidence of VTE
increased significantly (Ptrend = 0.014) to 16%, 17%, 38%, and
38%, respectively (Table 3).
Risk Factors for the Development of VTE
Before Starting Treatment
Venous thromboembolism developed before starting
treatment in 31 patients (24.2%) (DVTalone, n = 20; DVTwith
PE, n = 8; PE alone, n = 3), and the rate of subclinical disease
was 96.8%. Screening was performed according to a DD level
with a negative predictive value of 96.1%.12 Nonetheless,
patients with silent PE alone were likely overlooked among
the patients who did not undergo CT because no DVT was
identifiedVwe consider that the rate is extremely low.
Mean (SD) DD level was 7.4 (6.4) Kg/mL in patients
with VTE, which is significantly higher than in patients
without VTE (3.2 [5.0] Kg/mL; P G 0.001). Venous throm-
boembolism developed in 34.0% (18/53) of the patients with
CCC, which is significantly higher than the incidence of
17.3% (13/75) among patients with non-CCC (P = 0.03).
Tissue factorYpositive patients developed VTE at an inci-
dence of 31.0% (22/71), which is significantly higher than
the incidence of 15.8% (9/57) in TF-negative patients (P =
0.0496). Comparison of the negative/weakly positive patient
group with the moderately/strongly positive patient group
showed a significant difference in VTE incidences, at 16.3%
(13/80) and 37.5% (18/48; P = 0.01), respectively. The ITFE
was therefore entered into the multivariate analysis using
those 2 groups (negative/weakly positive vs moderately/strongly
positive). A strong correlation was found between CCC and
ITFE, and because multicollinearity was seen (Spearman cor-
relation coefficient, 0.66), simultaneous incorporation of CCC
and ITFE in the multivariate analysis model was considered
statistically inappropriate. Accordingly, when ITFEwas selected
TABLE 1. Patient characteristics (N = 128)
Age, mean (SD), y 56.6 (11.3)
BMI, mean (SD), kg/m2 22.4 (3.4)
DD, mean (SD), Kg/mL 4.2 (5.6)
FIGO stage, n (%)
I 55 (43)
II 22 (17)
III 37 (29)
IV 14 (11)
Histology, n (%)
Serous carcinoma 42 (33)
CCC 53 (41)
Endometrioid carcinoma 15 (12)
Mucinous carcinoma 12 (9)
Undifferentiated carcinoma 6 (5)
FIGO, International Federation of Gynecology and Obstetrics;
SD, standard deviation.
TABLE 2. Patient characteristics according to ITFE in cancer tissues
ITFE
P*
Negative
(N = 57)
Weakly Positive
(N = 23)
Moderately Positive
(N = 32)
Strongly Positive
(N = 16)
Age, mean (SD), y 56.4 (11.8) 55.6 (13.6) 58.3 (9.9) 55.5 (9.6) 0.797
BMI, mean (SD), kg/m2 22.8 (3.6) 22.7 (3.9) 21.9 (2.8) 21.4 (2.6) 0.376
DD, mean (SD), Kg/mL 4.3 (5.6) 3.1 (4.6) 4.8 (6.1) 4.5 (6.6) 0.723
FIGO stage, n (%)
I 10 (18.2) 16 (29.1) 18 (32.7) 11 (20.0) G0.001
II 12 (54.5) 2 (9.1) 5 (22.7) 3 (13.6)
III 26 (70.3) 5 (13.5) 5 (13.5) 1 (2.7)
IV 9 (64.3) 0 (0) 4 (28.6) 1 (7.1)
Histology, n (%)
CCC 3 (5.7) 10 (18.9) 25 (47.2) 15 (28.3) G0.001
Non-CCC 54 (72.0) 13 (17.3) 7 (9.3) 1 (1.3)
*Analyzed using Student t test for continuous variables and Fisher exact test for categorical variables.
FIGO, International Federation of Gynecology and Obstetrics; SD, standard deviation.
TABLE 3. Incidence of VTE for each ITFE
Incidence of VTE, n (%) P
ITFE 0.014
Negative 9/57 (15.8)
Weakly positive 4/23 (17.4)
Moderately positive 12/32 (37.5)
Strongly positive 6/16 (37.5)
Ptrend = 0.014.
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as the factor with the lowerP value andmultivariate analysis was
performed, the results showed that pretreatment DD level and
ITFE represented significant independent risk factors for the
development of VTE before the start of treatment (Table 4). We
also examined the impact of histology and TF on VTE devel-
opment before the start of treatment by early- and advanced-
stage diseases. Although no significant difference was seen
between CCC and non-CCC in either early- or advanced-stage
diseases, a tendency was seen for VTE development to increase
in CCC. When TF was moderately/strongly positive, no sig-
nificant difference was seen in early-stage diseases, but a ten-
dency toward an increased risk of VTE development was seen.
In advanced-stage diseases, the risk of VTE development was
significantly increased (P = 0.021; Table 5).
DISCUSSION
This study was able to confirm that TF is involved in the
pretreatment development of VTE in EOC, particularly in CCC.
Uno et al8 studied 32 patients with ovarian cancer and
revealed a relationship between TF expression in tumor tis-
sues and the development of VTE before the start of treat-
ment. However, that result was only shown in univariate
analysis because of the small size of the study cohort. This
study focused on EOC as the histological type and enrolled
4 times as many patients, enabling multivariate analysis but
generating the same results and confirming the earlier find-
ings. We were also able to verify that the incidence of VTE
development before the start of treatment increased signifi-
cantly as ITFE increased. Tissue factor binds to blood co-
agulation factor VII, which is released on damage to the
vascular endothelial cells and others and promotes extrinsic
coagulation.13 We surmised that the mechanism involves TF
present in tumors being released into the blood vessels and
leading to an increased incidence of VTE development.
Uno et al8 reported pretreatment VTE development in
45.5% (5/11) of patientswith CCC, which is significantly higher
than the frequency in patients with non-CCC. Some subsequent
studies found development rates of 15% to 42%,14Y16 which
TABLE 4. Logistic regression analysis for VTE
Characteristics
Univariate Multivariate
Incidence, % OR (95% CI) P Adj OR (95% CI) P
Age, y
G60 17/81 (21.0) Reference 0.26
Q60 14/47 (29.8) 1.60 (0.70Y3.64)
BMI, kg/m2
G25 28/108 (25.9) Reference 0.30
Q25 3/20 (15.0) 0.50 (0.14Y1.85)
Expression of TF
Negative 9/57 (15.8) Reference 0.014
Weakly positive 4/23 (17.4) 1.60 (1.10Y2.32)
Moderately positive 12/32 (37.5) -
Strongly positive 6/16 (37.5) -
Negative 9/57 (15.8) Reference 0.049
Positive 22/71 (31.0) 2.39 (1.00Y5.73)
Negative/weakly positive 13/80 (16.3) Reference 0.008 Reference 0.007
Moderately/strongly positive 18/48 (37.5) 3.09 (1.34Y7.11) 3.59 (1.43Y8.99)
Stage (FIGO)
I/II 19/77 (24.7) Reference 0.88
III/IV 12/51 (23.5) 1.00 (0.96Y1.04)
Histology
Non-CCC 13/75 (17.3) Reference 0.03
CCC 18/53 (34.0) 2.45 (1.07Y5.60)
Serous carcinoma 7/42 (16.7) Reference 0.17
Nonserous carcinoma 24/86 (27.9) 1.94 (0.76Y4.95)
Pretreatment plasma DD level, Kg/mL
G2.0 8/74 (10.8) Reference G0.0001 Reference G0.0001
Q2.0 23/54 (42.6) 6.25 (2.44Y14.3) 3.59 (1.43Y8.99)
Adj, adjusted; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; OR, odds ratio.
International Journal of Gynecological Cancer & Volume 27, Number 1, January 2017 Tissue Factor Develops VTE
* 2016 IGCS and ESGO 41
are higher than those in patients with non-CCC. Likewise, this
study found pretreatment VTE development in 33.9% (18/53)
of patients with CCC and confirmed that the rate was signif-
icantly elevated. The possibility was suggested that the histo-
logical type of ovarian cancer represents a confounding factor
that skews TF expression and VTE development. For that
reason, this study applied multivariate analysis using 2 factors:
ITFE with a lower P value and pretreatment DD level. That
analysis confirmed both factors as significant risk factors (TF,
P = 0.007; DD level, P G 0.0001).Moreover, whenmultivariate
analysis was performed for CCC and DD level, both represented
significant risk factors (CCC, P = 0.014; DD level, P G 0.0001).
We saw no significant difference in histology in our examination
of the respective impacts of histology and TF on VTE devel-
opment before the start of treatment of early- and advanced-stage
diseases. In advanced-stage diseases, TFexpression significantly
increased the risk of VTE development (P = 0.021), suggesting
that the impact of TF expression on VTE development is more
evident in advanced-stage diseases.
Tissue factor is involved in the early stages of thrombus
formation via the extrinsic coagulation process and can be
regarded as the cause of VTE. D-dimer is a degradation
product remaining after fibrin formation14 and can be regarded
as merely a result of thrombus formation. Accordingly, the
production of TF by EOC can be considered an essential risk
factor for the pretreatment development of VTE.
We were able to confirm that TF is particularly mark-
edly expressed in CCC compared with other histological
types of EOC. In the report by Uno et al,8 the 15 NAC-treated
patients accounted for nearly half of the total 32 patients, and
the possibility that the effects of anticancer agents in the
analyzed tissue specimens had biased the results of TF im-
munostaining was thus unable to be excluded. No pretreatment
biopsies were taken from patients with EOC undergoing NAC
at our hospital if cancer of the ovaries, fallopian tubes, or
peritoneum was suspected on image diagnosis; if cells con-
sistent with a malignant surface epithelial-stromal tumor were
seen in an aspiration cytology of the tumor, pleural effusion, or
ascites; or if biopsy and advanced-stage diagnosis by micros-
copy during NAC could be skipped because the patient met
the criteria of CA125 of greater than 200 U/mL and carcino-
embryonic antigen of less than 20 ng/mL.9,17,18
This study ruled out such potential bias by excluding
patients who had received NAC and studying only specimens
obtained before the administration of anticancer agents. We
thus consider that the present report has greater credibility with
regard to the evaluation of TF expression in patients with EOC.
In summary, this study confirmed that (1) TF expression
in tumors represents an independent, significant risk factor for
the pretreatment development of VTE, with a stronger influ-
ence in advanced stages; (2) increases in ITFE are followed by
an increased incidence of VTE development; (3) both the in-
cidence and ITFE are higher in CCC than in non-CCC; and (4)
CCC shows a higher incidence of pretreatment VTE devel-
opment compared with non-CCC. These findings strongly
suggest that the high ability of CCC to produce TF is involved
in the pretreatment development of VTE in CCC.
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